Evidence map›Paper›PMID 36508283›Full record

ArticleBlood advances2023

Novel risk assessment for the intensity of conditioning regimen in older patients.

Yu Akahoshi, Yuma Tada, Emiko Sakaida, Machiko Kusuda, Noriko Doki, Naoyuki Uchida, Takahiro Fukuda, Masatsugu Tanaka, Masashi Sawa, Yuta Katayama and 7 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 2 countries.

Yu AkahoshiDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0001-6825-9340
Yuma TadaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.ORCID 0000-0002-7254-1928
Machiko KusudaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID 0000-0002-8661-3179
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Takahiro FukudaDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Aichi, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan.ORCID 0000-0001-5054-9104
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Aichi, Japan.
Makoto OnizukaDepartment of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6704-3633
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.
Hideki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0001-5812-9315
Jichi Medical University · JPAichi Medical University · JPAnjo Kosei Hospital · JPChiba University Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPKanagawa Prefectural Hospital Organization · JPKyoto University · JPOkayama University Hospital · JPOsaka International Cancer Institute · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reduced-intensity conditioning (RIC) regimens have long-term outcomes that are generally comparable with those of myeloablative conditioning (MAC) because of a lower risk of nonrelapse mortality (NRM) but a higher risk of relapse. However, it is unclear how we should select the conditioning intensity in individual cases. We propose the risk assessment for the intensity of conditioning regimen in elderly patients (RICE) score. We retrospectively analyzed 6147 recipients aged 50 to 69 years using a Japanese registry database. Based on the interaction analyses, advanced age (≥60 years), hematopoietic cell transplantation-specific comorbidity index (≥2), and umbilical cord blood were used to design a scoring system to predict the difference in an individual patient's risk of NRM between MAC and RIC: the RICE score, which is the sum of the 3 factors. Zero or 1 implies low RICE score and 2 or 3, high RICE score. In multivariate analyses, RIC was significantly associated with a decreased risk of NRM in patients with a high RICE score (training cohort: hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.60-0.90; P = .003; validation cohort: HR, 0.57; 95% CI, 0.43-0.77; P < .001). In contrast, we found no significant differences in NRM between MAC and RIC in patients with a low RICE score (training cohort: HR, 0.99; 95% CI, 0.85-1.15; P = .860; validation cohort: HR, 0.81; 95% CI, 0.66-1.01; P = .061). In summary, a new and simple scoring system, the RICE score, appears to be useful for personalizing the conditioning intensity and could improve transplant outcomes in older patients.

Indexed as

Leukemia, Myeloid, AcuteNeoplasm Recurrence, LocalAgedHumansRetrospective StudiesRisk AssessmentTransplantation Conditioning

Identifiers

PMID36508283
PMCPMC10468368
OpenAlexW4311201315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.